Results 161 to 170 of about 33,653 (199)
Some of the next articles are maybe not open access.
Targeting ERBB Receptors in Cancer
2007Tyrosine kinases are a large and diverse family of proteins found only in metazoans. The ERBB family, which encompasses subgroup I of the receptor tyrosine kinase (RTK) superfamily, has four members: epidermal growth factor receptor (EGFR)/ErbB1, ErbB2, ErbB3, and ErbB4.
openaire +2 more sources
Cytohesins are cytoplasmic ErbB receptor activators.
Cell, 2010Signaling by ErbB receptors requires the activation of their cytoplasmic kinase domains, which is initiated by ligand binding to the receptor ectodomains. Cytoplasmic factors contributing to the activation are unknown. Here we identify members of the cytohesin protein family as such factors.
Bill, A. +15 more
openaire +4 more sources
2015
In metazoa, inductive cell-to-cell interactions play crucial roles, both in embryonic development and in homeostasis. Many such interactions are mediated by RTKs and their soluble or surface-bound ligand growth factors. Type 1 RTKs, also called the ERBB or HER family, comprises four proteins, which bind growth factors of the EGF and neuregulin families.
Fresia Pareja, Gur Pines, Yosef Yarden
openaire +1 more source
In metazoa, inductive cell-to-cell interactions play crucial roles, both in embryonic development and in homeostasis. Many such interactions are mediated by RTKs and their soluble or surface-bound ligand growth factors. Type 1 RTKs, also called the ERBB or HER family, comprises four proteins, which bind growth factors of the EGF and neuregulin families.
Fresia Pareja, Gur Pines, Yosef Yarden
openaire +1 more source
Effector mechanisms of therapeutic antibodies against ErbB receptors
Current Opinion in Immunology, 2008ErbB1 and ErbB2 constitute validated target antigens for tumor therapy-as documented by the approval of antibodies and tyrosine kinase inhibitors (TKIs) against both antigens. However, their complex biology in development and tumorigenesis poses significant challenges on the optimization of this targeted approach.
Matthias, Peipp +2 more
openaire +2 more sources
Neuregulins and ErbB receptors in cultured neonatal astrocytes
Journal of Neuroscience Research, 1999Neuregulins (NRGs) are a family of growth factors involved in signaling between neurons and glial cells of the peripheral and central nervous system. NRGs are synthesized and secreted by a number of cell types including Schwann cells, neurons, and oligodendrocytes.
A, Francis +3 more
openaire +2 more sources
ErbB Receptor Negative Regulatory Mechanisms: Implications in Cancer
Journal of Mammary Gland Biology and Neoplasia, 2006Activation of ErbB receptor tyrosine kinases (RTKs) must be precisely regulated to ensure the fidelity of developmental and homeostatic processes mediated by growth factors. Insufficient receptor stimulation will lead to defects in tissue development, while excessive stimulation can lead to hyperplastic events associated with cancer and other diseases.
Colleen, Sweeney +3 more
openaire +2 more sources
Localization and modulation of ErbB receptor tyrosine kinases
Current Opinion in Cell Biology, 2001The ErbB family of receptor tyrosine kinases serves as a model for understanding the propagation of growth factor signals across the plasma membrane and the interpretation of those signals into a cellular response. Recent studies point to a critical role for the accumulation of ErbBs at specific cell-surface locations in the fidelity of ErbB signaling.
K L, Carraway, C, Sweeney
openaire +2 more sources
Nuclear ErbB Receptors: Pathways and Functions
2008Accumulating evidence suggests a new mode of ErbB receptor signaling in which intact or fragmented ErbB receptors traffic from the cell surface to the nucleus following the addition of a cognate ligand. In the nucleus, ErbB receptors have a role, probably indirect, in modulating gene expression.
Hong-Jun Liao, Graham Carpenter
openaire +1 more source
[Targeting ErbB receptors in breast cancer].
Bulletin du cancer, 2007Because of the involvement of the receptors of the ErbB family in breast oncogenesis, numerous approaches aimed at targeting these receptors have been developed. A monoclonal antibody directed against the ErbB2 (HER2) receptor, trastuzumab (Herceptin), has shown a high activity in palliative, neo-adjuvant and, more recently, in adjuvant setting, and ...
Pierre, Fumoleau +5 more
openaire +1 more source
Integrative oncology: Addressing the global challenges of cancer prevention and treatment
Ca-A Cancer Journal for Clinicians, 2022Jun J Mao,, Msce +2 more
exaly